Milan Radovich, Ph.D., Chief Scientific Officer at Caris Life Sciences, summarizes the company’s comprehensive clinico-genomic database being used to advance targeted therapy for various cancer types.
As noted by Dr. Radovich, Caris performed whole genome sequencing of cancer patients to look at all 22,000 genes. Researchers then examined them in relation to cancer types and severity. At ASCO 2023, numerous abstracts were presented that represent 42 studies involving over 30 cancer types. The findings of these studies show how comprehensive molecular profiling to identify molecular changes can affect tumor behavior and patient outcomes.
The Program, called the Caris Precision Oncology Alliance (POA), includes partnerships with 83 cancer centers and academic institutions. Their goal is to advance targeted therapies for various cancers.
To stay up-to-date on the latest development, sign up for our newsletter at checkrare.com/sign-up-for-our-newsletter/